Ginkgo Bioworks reported Q4 revenues of $33 million, down 24% year-over-year, and missing estimates by over $4 million. Cell Engineering, expected to drive growth, delivered just $125 million in 2025 ...

Law360 is on it, so you are, too. A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are ...

Ginkgo Bioworks' Q3 results reveal uncertainty in its near-term future, with a disappointing performance in its Cell Engineering segment. The company's revenue has been heavily reliant on its ...

Ginkgo Bioworks (DNA) went public last September through an SPAC deal with Soaring Eagle Acquisition Corporation, a blank-check company led by former MGM CEO Harry Sloan. However, the stock has ...